Teva Pharmaceutical Industries (NYSE:TEVA) Downgraded by StockNews.com to Buy

StockNews.com cut shares of Teva Pharmaceutical Industries (NYSE:TEVA) from a strong-buy rating to a buy rating in a research report report published on Wednesday.

A number of other brokerages have also recently issued reports on TEVA. JPMorgan Chase & Co. increased their target price on shares of Teva Pharmaceutical Industries from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Monday, October 21st. UBS Group lifted their price objective on Teva Pharmaceutical Industries from $24.00 to $26.00 and gave the stock a “buy” rating in a report on Tuesday, September 3rd. Finally, Barclays boosted their target price on Teva Pharmaceutical Industries from $25.00 to $28.00 and gave the stock an “overweight” rating in a research report on Wednesday. Two equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $20.88.

Teva Pharmaceutical Industries Stock Performance

NYSE:TEVA opened at $21.20 on Wednesday. The firm’s fifty day simple moving average is $17.61 and its 200-day simple moving average is $17.45. The company has a quick ratio of 0.61, a current ratio of 0.89 and a debt-to-equity ratio of 2.57. The stock has a market cap of $24.02 billion, a PE ratio of -24.94, a price-to-earnings-growth ratio of 0.99 and a beta of 0.79. Teva Pharmaceutical Industries has a fifty-two week low of $10.13 and a fifty-two week high of $21.98.

Insider Activity

In other news, EVP Christine Fox sold 19,388 shares of the business’s stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $16.87, for a total value of $327,075.56. Following the completion of the transaction, the executive vice president now owns 44,104 shares of the company’s stock, valued at $744,034.48. The trade was a 30.54 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 0.55% of the company’s stock.

Institutional Trading of Teva Pharmaceutical Industries

Several hedge funds and other institutional investors have recently bought and sold shares of TEVA. UMB Bank n.a. boosted its holdings in shares of Teva Pharmaceutical Industries by 555.6% during the third quarter. UMB Bank n.a. now owns 2,439 shares of the company’s stock worth $44,000 after purchasing an additional 2,067 shares during the last quarter. Smithfield Trust Co boosted its stake in Teva Pharmaceutical Industries by 55.7% in the 3rd quarter. Smithfield Trust Co now owns 2,739 shares of the company’s stock worth $50,000 after buying an additional 980 shares during the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in Teva Pharmaceutical Industries in the 3rd quarter valued at about $50,000. Claro Advisors LLC acquired a new position in shares of Teva Pharmaceutical Industries during the 3rd quarter valued at about $52,000. Finally, Mark Sheptoff Financial Planning LLC purchased a new position in shares of Teva Pharmaceutical Industries during the 2nd quarter worth about $57,000. 54.05% of the stock is owned by hedge funds and other institutional investors.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.